Great advance in the field for #NET patients
Reposted from NEJM.org
Cabozantinib, as compared with placebo, doubled median progression-free survival in patients with extrapancreatic neuroendocrine tumors and tripled it in those with pancreatic neuroendocrine tumors. Full CABINET trial results and Research Summary: nej.md/3AYuEoI

#MedSky #Oncology

Comments

Posting Rules

  • Be respectful to others
  • No spam or self-promotion
  • Stay on topic
  • Follow Bluesky's terms of service